Eye Drops Instead of Eye Injections for Dry AMD: What the Trials Are Actually Testing
Eye Drops for Dry AMD at a Glance
If you have dry age-related macular degeneration (AMD) and you have heard that eye drops might one day replace injections, here is the honest picture. Today, the only approved medicines for geographic atrophy, the advanced form of dry AMD, are given by injection into the eye, monthly or every other month.1 Eye drops for dry AMD are still being studied in clinical trials, which means they are not yet proven and not yet available at your eye doctor's office. That is disappointing to hear, but knowing where the research really stands helps you make calm decisions now instead of waiting on a product that has not arrived.
An eye drop you could put in at home is attractive for one simple reason: the current treatments are demanding. People on the approved geographic atrophy injections can expect ongoing treatment about every 4 to 8 weeks, in many cases in both eyes.1 That is a lot of clinic visits, and for many people transportation and time off are real barriers. A drop would lower that burden, which is exactly why several research groups are chasing it. It is a worthwhile goal, and it is also a hard one, for reasons we explain below.
While drops remain investigational, the steps that already help are worth taking. If you have intermediate AMD, special dietary supplements (specific vitamins and minerals) may be able to stop it from turning into late AMD.2 Keeping your regular eye appointments, not smoking, and using an Amsler grid at home to watch for change all remain sensible. None of this restores lost vision, but it gives you the best odds of protecting the vision you have while the science moves forward.
What Dry AMD and Geographic Atrophy Are
AMD affects the macula, the small central part of the retina you use for reading, faces, and fine detail. Geographic atrophy is a later-stage form of dry age-related macular degeneration.3 In it, patches of the light-sensing tissue and its support cells thin out and stop working, and those patches slowly widen over time. Most people notice this gradually rather than suddenly, which is part of why regular monitoring matters.
It helps to be clear-eyed about what treatment can and cannot do. Vision loss caused by geographic atrophy is permanent and cannot be reversed.3 That sounds bleak, but it is also why the whole research effort, drops included, aims to slow the damage rather than undo it. In the meantime, most people keep useful side (peripheral) vision, and low-vision tools like magnifiers and better lighting help many people keep reading and living independently.
You do not diagnose or track this at home on your own. Geographic atrophy is diagnosed with an eye exam and retinal imaging such as optical coherence tomography (OCT).3 These scans let your eye doctor measure the atrophy and see whether it is growing, which is the same measurement the drug trials rely on. That is why staying in regular care is the single most useful thing you can do while new treatments are tested.
What the Dry AMD Eye-Drop Trials Are Testing
The hardest part of a dry AMD drop is not the drug, it is getting the drug to the back of the eye. Because of barriers such as tear turnover, the cornea, and the blood-retinal barrier, topical eye-drop formulations are inefficient at delivering drugs to the retina.4 In plain terms, most of a drop is blinked and drained away in minutes, and what is left has several walls to cross before reaching the macula. Trials are testing new formulations designed to survive that journey, which is why an eye drop for the retina is harder to build than one for the surface of the eye.
Injection is effective partly because it puts the drug where it is needed, but it is not the only route being explored. Less invasive delivery routes than intravitreal injection, including topical eye drops, are being evaluated by researchers.4 The candidate drops in these studies aim to reach the retina and either slow the spread of atrophy or help protect the vulnerable cells. Because they are experimental, the trials are first asking whether the drops are safe and whether enough drug even reaches the target, before asking whether they help vision.
It is worth understanding what 'it worked' means in this research, because the bar is specific. In the trials that led to the approved geographic atrophy injections, treatment slowed growth of the atrophy but failed to delay loss of best-corrected visual acuity and reading ability.1 The main measured target is the size of the atrophy on imaging, not how well you can read an eye chart. The drop trials are chasing that same anatomic target, so a positive early result would mean slower atrophy growth, which is not the same as restored sight.
How Strong Is the Evidence for Eye Drops Right Now
The most important thing to know is also the simplest. Researchers are still working to find new treatment options for late dry AMD.2 No eye drop has yet been approved for dry AMD, so the only approved treatments remain the injections described above. Promising laboratory results and early-phase studies are genuine reasons for optimism, but they are not the same as proof that a drop helps people.
When you read a headline about a trial, look for what was actually measured. A study that shrinks how fast a lesion grows on a scan is measuring the disease, not your day-to-day sight, and the two do not always move together. That gap is exactly why the approved injections are debated even though they passed their trials, and it is the same question every drop will have to answer. Treat early trial news as a reason to stay in care and stay informed, not as a reason to change what you are doing today.
Risks, Trade-offs, and a Realistic Outlook
Part of why drops are wanted is that the current injections are not risk-free. Some patients who received pegcetacoplan injections developed new-onset wet (exudative) AMD.1 Other uncommon risks of any eye injection include inflammation and, rarely, infection, which is why these treatments are given by a specialist and monitored closely. If a future drop lowered these risks while still slowing atrophy, that would be a meaningful advance, but that is a hope the trials still have to prove.
Geographic atrophy usually progresses gradually over years rather than overnight, and outcomes vary a lot from person to person. On average, people lose central detail slowly while keeping peripheral vision, but this is a population pattern and not a prediction about you specifically. The realistic plan is to slow progression where possible, adapt with low-vision support, and stay eligible for new options, including trials, as they mature.
Even proven treatments raise practical questions, and future drops will too. Investigational drops are only available inside clinical trials right now, at no charge for the study drug but with the time commitment any trial requires. If and when a drop is approved, its price, insurance coverage, and availability will shape who can actually use it, just as they do for today's injections. Your eye care team and patient advocacy groups can help you find trials and understand coverage as things change.
When to Call Your Eye Doctor
Dry AMD is usually slow, so a sudden change deserves attention rather than alarm. If you notice a new blind spot, straight lines that suddenly look wavy or bent, or a rapid drop in your central vision, call your eye doctor promptly, because these can signal a switch to wet AMD, which is more treatable when caught early. Wet AMD is treated with anti-VEGF medicines that a doctor injects into the eye, which may help stop further vision loss.2 A retina specialist usually provides that treatment, so getting checked quickly gives you the best chance of protecting your vision.
Most of your care will be routine, and keeping those visits is what makes early problems catchable. Ask your eye doctor how often you should be seen, use your Amsler grid on the schedule they give you, and report changes rather than waiting for the next appointment. This steady monitoring is also how you stay a candidate for new treatments and trials.
Common Questions About Dry AMD Eye Drops
No. Eye drops for dry AMD are investigational, meaning they have not been proven to work and are not available outside of research studies. Stopping a treatment your doctor recommends, in order to wait for something that may be years away and may not pan out, can cost you vision you cannot get back. If the injection burden is hard for you, talk to your retina specialist about the real trade-offs rather than pausing care on your own.
Not through legitimate channels. A drop that is still in trials cannot be bought, and any product marketed directly to you as a proven dry AMD cure should be treated with real caution. The only way to access an investigational drop today is by qualifying for and enrolling in a clinical trial, where it is provided as part of the study. Your eye doctor can tell you whether any trials are recruiting near you.
The target sits at the very back of the eye, behind several natural barriers. A drop on the eye's surface is mostly cleared within minutes, and the small amount that remains has to cross the cornea and the blood-retinal barrier to reach the macula. Getting a useful dose that far, reliably and safely, is the core problem the trials are working to solve, which is why progress has been slower than many people hoped.
Not necessarily. These studies mainly measure whether the atrophy grows more slowly on retinal scans, which is a measure of the disease rather than of your eyesight. Slowing the damage is valuable, but it is not the same as restoring sight already lost. When you read trial news, look for whether the study measured real-world vision and reading, not only the size of the lesion, before drawing conclusions.
More Questions About Eye Drops and Dry AMD
They can play a role for the right person. Specific vitamin and mineral formulas are used to lower the chance that intermediate dry AMD progresses to the late stage, though they do not restore vision and are not right for everyone. Ask your eye doctor whether a supplement formula fits your stage of AMD before you start one, since the benefit depends on where you are in the disease.
Start with your own eye care team, since retina specialists often know which studies are recruiting. You can also search public trial registries and ask patient advocacy organizations that focus on macular degeneration. Before enrolling, ask what the study is measuring, what is expected of you, what the possible risks are, and what happens when the trial ends, so you can decide with clear expectations.
Not automatically. A drop avoids the needle, which is a genuine advantage, but any medicine strong enough to reach and act on the retina can have its own side effects, and those are exactly what early trials test for first. Safety is not assumed from the delivery method; it has to be demonstrated. That is one reason a drop cannot skip the trial process even though it seems gentler.
Usually not suddenly, but it is worth knowing the warning signs. Dry AMD typically changes slowly, so most of your care is routine monitoring rather than urgent action. The change to watch for is a fast shift, such as a new blind spot or lines that suddenly look wavy, which can mean a switch to wet AMD and should prompt a prompt call. Caught early, that switch is often treatable, so knowing the signs protects you.
- What stage of dry AMD do I have, and is any part of it geographic atrophy?
- Would a supplement formula be appropriate for my stage, and if so which one?
- How often should I be seen, and how should I use an Amsler grid at home?
- Are there any clinical trials I might qualify for, and what would they involve?
- What specific changes in my vision should make me call you right away?
- American Academy of Ophthalmology, EyeNet Magazine (2024). New Geographic Atrophy Drugs: The Good, the Bad, and the Unknown.
- National Eye Institute (NEI) (2024). Age-Related Macular Degeneration (AMD).
- Cleveland Clinic (2024). Geographic Atrophy: Symptoms, Causes & Treatment.
- Pharmaceutics (PMC full text) (2021). Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.